Atea Pharmaceuticals, Inc.
AVIR
$3.07
$0.010.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 122.62M | 118.05M | 116.19M | 109.11M | 80.49M |
| Gross Profit | -122.62M | -118.05M | -116.19M | -109.11M | -80.49M |
| SG&A Expenses | 48.85M | 47.02M | 48.58M | 49.54M | 49.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 171.47M | 165.07M | 164.77M | 158.65M | 130.41M |
| Operating Income | -171.47M | -165.07M | -164.77M | -158.65M | -130.41M |
| Income Before Tax | -167.46M | -172.96M | -174.95M | -162.61M | -134.94M |
| Income Tax Expenses | 925.00K | 1.05M | 1.04M | 1.05M | 1.02M |
| Earnings from Continuing Operations | -168.39 | -174.01 | -176.00 | -163.66 | -135.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -168.39M | -174.01M | -176.00M | -163.66M | -135.96M |
| EBIT | -171.47M | -165.07M | -164.77M | -158.65M | -130.41M |
| EBITDA | -171.05M | -164.66M | -164.35M | -158.23M | -130.00M |
| EPS Basic | -2.00 | -2.07 | -2.10 | -1.96 | -1.63 |
| Normalized Basic EPS | -1.08 | -1.02 | -1.01 | -0.96 | -0.76 |
| EPS Diluted | -2.00 | -2.07 | -2.10 | -1.96 | -1.63 |
| Normalized Diluted EPS | -1.08 | -1.02 | -1.01 | -0.96 | -0.76 |
| Average Basic Shares Outstanding | 337.06M | 336.03M | 335.01M | 334.15M | 333.57M |
| Average Diluted Shares Outstanding | 337.06M | 336.03M | 335.01M | 334.15M | 333.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
